Beauchemin Nicole, Arabzadeh Azadeh
Goodman Cancer Research Centre, McGill University, Montreal, Canada,
Cancer Metastasis Rev. 2013 Dec;32(3-4):643-71. doi: 10.1007/s10555-013-9444-6.
The discovery of the carcinoembryonic antigen (CEA) as a tumor marker for colorectal cancer some 50 years ago became the first step in the identification of a much larger family of 12 carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) with surprisingly diverse functions in cell adhesion, in intracellular and intercellular signaling, and during complex biological processes such as cancer progression, inflammation, angiogenesis, and metastasis. The development of proper molecular and biochemical tools and mouse models has enabled bidirectional translation of the CEACAM network biology. Indeed, CEACAM1, CEACAM5, and CEACAM6 are now considered valid clinical biomarkers and promising therapeutic targets in melanoma, lung, colorectal, and pancreatic cancers. These fascinating proteins illustrate how a better understanding of the CEACAM family of cell adhesion molecules reveals their functional link to the underlying disease and lead to new monitoring and targeting opportunities.
大约50年前，癌胚抗原（CEA）作为结直肠癌的肿瘤标志物被发现，这成为鉴定一个更大的由12种癌胚抗原相关细胞粘附分子（CEACAMs）组成的家族的第一步。这些分子在细胞粘附、细胞内和细胞间信号传导以及癌症进展、炎症、血管生成和转移等复杂生物学过程中具有惊人的多样功能。合适的分子和生化工具以及小鼠模型的开发，实现了CEACAM网络生物学的双向转化。事实上，CEACAM1、CEACAM5和CEACAM6现在被认为是黑色素瘤、肺癌、结直肠癌和胰腺癌有效的临床生物标志物和有前景的治疗靶点。这些迷人的蛋白质说明了更好地理解CEACAM细胞粘附分子家族如何揭示它们与潜在疾病的功能联系，并带来新的监测和靶向机会。
